While mTOR inhibitors (e.g., sirolimus) and AMPK activators (e.g., metformin) have shown promise in clinical trials for SLE and RA, their effects are often accompanied by off-target consequences, such as hyperlipidemia and infection risk, highlighting the need for more selective targeting. The gene discussed is MTOR; the disease is systemic lupus erythematosus.